Fu Hong Han Lin (02696) H Drug ESMO 2026 Sneak Peek: US Bridging Research Will Oral Release the World's First Anti-PD-1 Single Anti-Lung Cancer First-Line Treatment and Add New Evidence

^{The Zhitong Finance App learned that on October 19, 2026, local time, the European Society of Medical Oncology (ESMO) annual meeting announced the research summary. Fuhong Hanlin (02696)'s core product, an innovative anti-PD-1 monoclonal antibody H drug Hans-like® (Sululimab, European trade name Hetronifly®), was selected for this conference. Among them, the American Bridging ASTRIDE study will be showcased in the form of an oral report. It was approved for the first time in the world} Anti-PD-1 monoclonal antibodies for first-line treatment of extensive small cell lung cancer (ES-SCLC) complement key clinical evidence in the US population.

The ASTRIDE study is a head-to-head bridging test conducted in the US to compare the efficacy and safety of slulizumab combined chemotherapy with atilizumab for first-line treatment of extensive small cell lung cancer (ES-SCLC). The study is one of the largest ES-SCLC clinical trials that have now been enrolled in the US, and was carried out independently by the local team. Summary data showed that with a median follow-up of 14.1 months, the median overall survival (OS) of the slulizumab group was 12.4 months, which was superior to 10.2 months in the attirizumab group; the 24-month OS rates of the two groups were 32.2% and 17.6%, respectively. Overall safety was comparable, and no new safety signals were found. The results not only confirm the clinical benefits of slulizumab, but also support that the findings of the global multi-center phase III ASTRUM-005 study can be extrapolated to American patients.

Furthermore, H drugs have also made positive progress in the field of quality of life in lung cancer. Quality of life analysis results from ASTRUM-002 and ASTRUM-004 studies showed that sululizumab combined chemotherapy can prolong the time of deterioration of the overall health/quality of life of patients with non-small cell lung cancer, and is associated with improvements in various symptoms such as cough, dyspnea, and hemoptysis. In the field of gastrointestinal tumors, the ASTRUM-007 study showed that sululizumab combined chemotherapy did not adversely affect patients' quality of life; several researchers initiated clinical studies to explore the value of H drugs in different treatment stages of esophageal cancer and new adjuvant treatment for colorectal cancer. At the same time, H drug exploration in the field of extrapulmonary neuroendocrine cancer and kidney cancer also obtained positive data, which were published in the form of quick oral reports and posters, respectively.

As the world's first anti-PD-1 monoclonal antibody approved for first-line treatment of widespread small-cell lung cancer, H drug has now been approved for marketing in more than 50 countries and regions, covering nearly half of the global population, and included in local health insurance payment systems in more than 10 countries. Relying on the positive data from this US bridging study, the internationalization process of H drugs is expected to accelerate, bringing more immunotherapy options to patients with solid tumors around the world.